Cargando…

The pharmacotherapy of depression with EPA

Detalles Bibliográficos
Autor principal:	Puri, Basant K
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2991925/ http://dx.doi.org/10.1186/1744-859X-9-S1-S23

Ejemplares similares

EPA and Huntington's chorea: treatment and associated cerebral changes
por: Puri, Basant K
Publicado: (2010)

EPA in schizophrenia and violence
por: Treasaden, Ian H
Publicado: (2010)

Cognitive restructuring and improvement of symptoms with cognitive-behavioural therapy and pharmacotherapy in patients with depression
por: Marian, Mihai, et al.
Publicado: (2010)

Prevalence of cataract in adult Down's syndrome patients
por: Puri, Basant K, et al.
Publicado: (2010)

The structure, biosynthesis and functions of EPA: biomolecular neuropsychiatric aspects
por: Tsaluchidu, Sofia
Publicado: (2010)

Evaluation of pharmacotherapy in inpatients with mania in bipolar disorder
por: Piróg-Balcerzak, Agnieszka, et al.
Publicado: (2010)

EPA and the Perrin Technique: a combined approach to treating myalgic encephalomyelitis
por: Perrin, Raymond
Publicado: (2010)

Increased levels of ethane, a non-invasive, quantitative, direct marker of n-3 lipid peroxidation, in the breath of patients with schizophrenia
por: Puri, Basant K, et al.
Publicado: (2010)

The EPA/EADS/ESC position statement on diabetes and cardiovascular risk in patients with severe mental disorders
por: Möller, Hans-Jurgen
Publicado: (2010)

Structural brain changes in patients with Huntington's disease participating in a randomized, double-blind, placebo-controlled trial of ethyl-eicosapentaenoic acid
por: Puri, Basant K, et al.
Publicado: (2010)

Brain cell membrane motion-restricted phospholipids in patients with schizophrenia who have seriously and dangerously violently offended
por: Puri, Basant K, et al.
Publicado: (2010)

Improving access to alcohol use disorder pharmacotherapy and treatment in primary care settings
por: Hagedorn, Hildi, et al.
Publicado: (2015)

Regional grey matter volumetric changes in forensic schizophrenia patients: a magnetic resonance imaging study comparing the brain structure of patients who have seriously and violently offended with those of patients who have not
por: Puri, Basant K, et al.
Publicado: (2010)

A brief intervention targeting primary-care physician prescribing of pharmacotherapies for alcohol dependence: can it impact prescribing behavior and reduce hospital inpatient admissions?
por: Shakeshaft, Anthony
Publicado: (2012)

Use of pharmacotherapies for treatment resistant depression in finland: A nationwide cohort study
por: Taipale, H., et al.
Publicado: (2021)

Catatonia in a case of major depression resistant to pharmacotherapy. A case report
por: Gil Sánchez, C. M., et al.
Publicado: (2023)

EPA 2020 Abstracts, Part 2
Publicado: (2020)

PS232. Influence of alexithymia on the prognosis of patients with major depression treated using pharmacotherapy.
por: Mantani, Tomoyuki, et al.
Publicado: (2016)

EPA guidance on treatment of cognitive impairment in schizophrenia
por: Vita, A.
Publicado: (2023)

Study of the efficacy and safety of various pharmacotherapy regimens for atypical depression in the framework of bipolar affective disorder, recurrent depressive disorder, psychogenic depression
por: Verbitskaya, M., et al.
Publicado: (2022)

Adjunctive antidepressive pharmacotherapy in schizophrenia patients
por: Zink, M.
Publicado: (2021)

Metabolic alterations in patients with depression and their relationship to the etiology of depressive disorders
por: Kahl, Kail G
Publicado: (2010)

Bipolar mood disorder and treatment-resistant depression
por: Rybakowski, Janusz K
Publicado: (2010)

Https://cpaper.ctimeetingtech.com/epa21/submission/edit
por: Alonzo, D.
Publicado: (2021)

Pro-inflammatory markers predict response to sequential pharmacotherapy in major depressive disorder: a CAN-BIND-1 report
por: Husain, M. I., et al.
Publicado: (2023)

Pharmacotherapy for borderline personality disorder: A review
por: Lietor, M.D.C. Molina, et al.
Publicado: (2021)

Cost-effectiveness of psychotherapies and pharmacotherapies for mental disorders
por: McCrone, P.
Publicado: (2023)

Pharmacotherapy of high-risk population for developing psychosis
por: Mohr, P.
Publicado: (2023)

Temperament and major depressive disorder
por: Karam, Elie G, et al.
Publicado: (2010)

ICU staff level of depression
por: Bekridelis, A, et al.
Publicado: (2003)

Clinical presentation and prognostic factors in fat embolism syndrome
por: Puri, GD, et al.
Publicado: (1999)

Antiarrhythmic effect of interleukin-1 (IL-1) in conjunction with contractile depression
por: Schlegel, F, et al.
Publicado: (1999)

Treatment guidelines for acute bipolar depression
por: Fountoulakis, Konstantinos N
Publicado: (2010)

Are depressive residual symptoms independent of treatments?
por: Figueira, Maria Luisa
Publicado: (2010)

New guidelines on depression from NICE
por: Ohlsen, Ruth I
Publicado: (2010)

Asthma diagnosis and treatment – 1024. Prevalence of depression among asthma patients and effects of asthma control on severity of depression
por: Kumar, Poonam, et al.
Publicado: (2013)

Combining remote work and training: the experience of participating in the first Virtual EPA Gaining Experience Programme
por: Shalak, K.
Publicado: (2023)

Clinical lessons from GENDEP for the treatment of depression
por: Aitchison, Katherine J
Publicado: (2010)

Biological theory of depression in the light of new evidence
por: Papageorgiou, George
Publicado: (2010)

Sleep disturbance symptoms and their associations with alexithymia, depression and anxiety
por: Bratis, Dionisios, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_2b4ggg0m1gt5qlsoeu2n6vkkmc